Clinical trial · Observational
Chemoradiation-Induced Nausea and Emesis: Quality of Life
Chemoradiation-Induced Nausea and Emesis: A Prospective Study to Assess Patient Preferences and Quality of Life
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Requested by PI during yearly Continuing Review
Summary
Brief summary (as posted)
The primary objectives of this study are: 1. To assess the preferences of cancer patients scheduled to receive chemoradiation and caregiver controls for side-effects of chemoradiation. 1. To compare preferences of cancer patients to those of healthy individuals. 2. To compare how patients' preferences for side-effects of chemoradiation change over time. 2. To longitudinally assess the quality of life of cancer patients scheduled to receive chemoradiation. 3. To determine the impact of nausea and vomiting associated with chemoradiation on patients' quality of life and evaluate potential change throughout the duration of chemoradiation treatment.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anal Cancer | Malignant Anal Neoplasm | CURATED_EXACT | 0.92 |
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
| Vulvar Cancer | Malignant Vulvar Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Interview | Behavioral | — | UNRESOLVED |
| Questionnaire | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients
- description
- Patients receiving chemoradiation for abdominal-pelvic tumors.
- interventionNames
- Behavioral: Interview
- Other: Questionnaire
- label
- Caregiver Controls
- description
- Healthy controls with no prior cancer diagnosis.
- interventionNames
- Behavioral: Interview
Primary outcomes (1)
- measure
- Longitudinal Quality of Life + Symptom Assessment Data
- timeFrame
- Survey(s) & Interview(s) at baseline (beginning of chemoradiation treatment), 3 weeks after treatment starts, the last day of treatment, and at the first follow-up appointment after chemoradiation treatment ends.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients receiving 5 to 6-week course of chemoradiation for abdominal-pelvic tumors (gastric cancers, gastro-esophageal (GE) junction, pancreatic, cervix, vulvar, endometrial, or anal) using conventional fractionation \[(180cGy-200cGy per day)\] 2. Patients receiving concurrent abdominal-pelvic radiation and single agent or combination of cisplatin, paclitaxel, CPT-11, oxaliplatin or 5-FU, capecitabine, gemcitabine, or bevacizumab (Avastin). 3. Patients must be least 18 years of age 4. Controls must be individuals with no prior cancer diagnosis 5. Controls must be at least 18 years of age 6. Controls must be the caregivers of patients on this study Exclusion Criteria: 1. Patients who do not have a diagnosis of cervix, endometrial, vulvar or anal cancer 2. Patients who are not scheduled to receive chemoradiation treatment 3. Patients who are not at least 18 years of age 4. Controls - individuals who have a prior diagnosis of cancer (with the exception of non-melanoma skin cancer) 5. Controls - individuals who are not at least 18 years of age
References
Publications (0)
Data not yet available